v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)
 3 Months Ended
Mar. 29, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Restructuring charges/(credits):  
Employee terminations$15 $384 
Asset impairments28 173 
Exit costs
6 64 
Restructuring charges/(credits)(a)
49 621 
Integration costs and other(b)
51 57 
Restructuring charges and certain acquisition-related costs100 678 
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net
3 (59)
Additional depreciation––asset restructuring recorded in Cost of sales(c)
3 4 
Implementation costs recorded in our condensed consolidated statements of operations as follows(d):
  
Cost of sales15 20 
Selling, informational and administrative expenses36 6 
Research and development expenses38 24 
Total implementation costs89 50 
Total costs associated with acquisitions and cost-reduction/productivity initiatives$195 $673 
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $31 million for the three months ended March 29, 2026 (including charges of $47 million for our Realigning our Cost Base Program and credits of $22 million for our Manufacturing Optimization Program) and (ii) charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program).
(b)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(c)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(d)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
Schedule of Components and Changes in Restructuring Accruals
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
Costs		Asset
Impairment
Charges		Exit CostsAccrual
Balance, December 31, 2025(a)
$1,783 $— $127 $1,910 
Provision
15 28 6 49 
Utilization and other(b)
(330)(28)(12)(371)
Balance, March 29, 2026(c)
$1,467 $— $121 $1,588 
(a)Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.2 billion) and Other noncurrent liabilities ($431 million).